Spots Global Cancer Trial Database for Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
Official Title: A Phase 2 Study of Duvelisib Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi)
Study ID: NCT03370185
Interventions
Study Description
Brief Summary: This is a multi-center, single-arm, open-label, Phase 2 study of duvelisib, an orally bioavailable dual inhibitor of PI3K-δ,γ, in patients with CLL/SLL who have previously been treated with ibrutinib or another Bruton's Tyrosine Kinase Inhibitor (BTKi) and relapsed or were refractory to such therapy or discontinued such therapy due to toxicity.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Arizona Oncology, Tempe, Arizona, United States
Genesis Cancer Center, Hot Springs, Arkansas, United States
Moores UC San Diego Cancer Center, La Jolla, California, United States
Ingalls Memorial Hospital, Harvey, Illinois, United States
QUEST Research Institute, Royal Oak, Michigan, United States
St. Vincent Frontier Cancer Center, Billings, Montana, United States
Summit Medical Group, Morristown, New Jersey, United States
Medical Oncology Associates PS, WA, Spokane, Washington, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
